The $250M milestone and raised guidance confirm near-term cash flow strength, but the stock's reaction will depend on the trajectory of recurring YUPELRI revenue and progress on Roche collaboration (HSR clearance). Monitor Q4 for YUPELRI growth and any updates on ex-US Ziihera milestones.
Drugs in focus
ZYME drug pipeline →YUPELRI
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially marketed (FDA approved November 2018; China NMPA approved June 2025).
- Next catalyst
- None dated
What to watchYUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $31.46entry
- T+1 · 6d ago −7.60%α −8.92% · $29.07
- T+4 · todayOpen
- T+5 · in 10h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks reported Q3 2026 revenue of $256.5M (vs consensus $221.0M) and GAAP diluted EPS of $2.28, driven by a $250M milestone from Jazz for Ziihera's FDA approval. The company raised full-year 2026 revenue guidance to $337M-$351M and adjusted EBITDA to $176M-$190M, reflecting the milestone and Theravance Biopharma acquisition.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $256.5M vs $27.6M YoY, including $250M Ziihera milestone
- GAAP diluted EPS $2.28 vs $(0.26) YoY
- 2026 revenue guidance raised to $337M-$351M (prior $278M-$292M)
- 2026 adjusted EBITDA guidance raised to $176M-$190M (prior $114M-$128M)
- Closed Theravance Biopharma acquisition on Sep 23, 2026
- Repurchased 534,381 shares for $14.0M in Q3
- Roche collaboration for ZW209 with up to $718M in milestones plus royalties
Financial Impact
Q3 revenue $256.5M, GAAP net income $173.7M; full-year guidance raised by ~$59M at midpoint
Risk Factors
- Q3 revenue includes a one-time $250M milestone; recurring revenue from YUPELRI and royalties was only ~$3.8M
- Theravance integration costs and severance weighed on SG&A ($42.7M vs $14.1M YoY)
- Roche collaboration subject to HSR clearance; delay could impact ZW209 timeline
- Cash and equivalents $100.5M vs $228.8M at Dec 2025, partly due to buybacks and acquisition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398944 |
Track record
25 reports on ZYME
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Viewing Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers